With the new omicron strain fueling fear around the globe that the coronavirus is regaining momentum, makers of the world’s most successful vaccines are investigating whether they need to tweak their shots.
Over the last few days, Moderna, Pfizer-BioNTech, Johnson & Johnson and AstraZeneca revealed plans to address the threat posed by omicron, which emerged in South Africa and recently was detected in Australia, Israel, Hong Kong and parts of Europe. On Friday, the World Health Organization classified omicron as a “variant of concern.”